

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-0048US1	Application No. 10/576,849
	Applicant Brian Smith, et al.		
	Filing Date April 9, 2007	Group Art Unit 1624	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	7,105,523	09/12/2006	Stasch et al.			
	2	7,157,466	01/02/2007	McClure et al.			
	3	7,173,037	02/02/2007	Alonso-Alija et al.			
	4	7,211,591	05/01/2007	Tajima et al.			
	5	7,229,991	06/12/2007	Meria et al.			
	6	7,230,024	06/12/2007	Carpino et al.			
	7	7,232,823	06/19/2007	Carpino et al.			
	8	2003/0225057	12/04/2003	Jeffrey Smith, et al.			
	9	2005/0020573	01/27/2005	Smith, B. M. et al.			
	10	2007/0060568	03/15/2007	Smith, J. et al.			
	11	2007/0275949	11/29/2007	Smith, B. et al.			
	12	2008/0045502	02/21/2008	Burbaum, B.W et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	13	AU 515236	03/26/1981	Australia				
	14	GB 1247306	09/22/1971	Great Britain				
	15	GB 2133401	07/25/1984	Great Britain				
	16	EP 0096838	12/28/1983	Europe				
	17	EP 0080779	07/16/1986	Europe				
	18	SU 1238732	06/15/1986	USSR			Abstract	
	19	WO2007/120517	10/25/2007	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	20	Baindur, et al., "(±)-3-allyl-7-halo-8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines as Selective High Affinity D1 Dopamine Receptor Antagonists: Synthesis and Structure-Activity Relationship", J. Med. Chem., 35:67-72 (1992)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-0048US1	Application No. 10/576,849
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Brian Smith, et al.	
		Filing Date April 9, 2007	Group Art Unit 1624

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	21	Bickerdike, Michael J., "5-HT <sub>2C</sub> Receptor Agonists as Potential Drugs for the Treatment of Obesity" <u>Current Topics in Medicinal Chemistry</u> , Vol. 3:pages 885-897 (2003)
	22	Bs, M. et al., "Novel Agonists of 5HT <sub>2C</sub> Receptors. Synthesis and Biological Evaluation of Substituted 2-(Indol-1-yl)-1-methylethylamines and 2-(Indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved Therapeutics for Obsessive Compulsive Disorder, <i>Journal of Medicinal Chemistry</i> (1997), 40(17), 2762-2769
	23	Bosch, et al., "Studies on the Synthesis of Pentacyclic Strychnos Indole Alkaloids. Photocyclization of <i>N</i> -chloroacetyl-1,2,3,4,5,6-hexahydro- 1,5-methanoazocino [4,3- <i>b</i> ] Indole Derivatives", <i>Tetrahedron</i> , 41(12):2557-66 (1985)
	24	Bremner, "Seven Membered Rings", Institute for Biomolecular Science, Dept. of Chemistry, University of Wollongong; "Progress in Heterocyclic Chemistry 13", Pergamon Press, Ch. 7:340-77 (2001)
	25	Chumpradit, et al., "(±)-7-chloro-8-hydroxyl-1-(4'-[ <sup>125</sup> I]iodophenyl)-3-methyl-2,3,4,5-tetrahydro-1 <i>H</i> -3-benzazepine: A Potential CNS D-1 Dopamine Receptor Imaging Agent", <i>J. Med. Chem.</i> , 32:1431-5 (1989)
	26	Clark, et al., "1,9-alkano-bridged 2,3,4,5-tetrahydro-1 <i>H</i> -3-benzazepines with Affinity for the α <sub>2</sub> -Adrenoceptor and the 5-HT <sub>1A</sub> Receptor", <i>J. Med. Chem.</i> , 33:633-41 (1990)
	27	Clinical trial NCT00768612, "Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia Study", <a href="http://clinicaltrials.gov/ct2/show/record/NCT00768612">http://clinicaltrials.gov/ct2/show/record/NCT00768612</a>
	28	DeMarinis et al., "Development of an Affinity Ligand for Purification of α <sub>2</sub> -Adrenoceptors from Human Platelet Membranes", <i>J. Med. Chem.</i> , 27, 918-921 (1984)
	29	Dhonnchadha, et al., "Anxiolytic-like Effects of 5-HT <sub>2c</sub> Ligands on Three Mouse Models of Anxiety", <i>Pharmacol. Biochem. Behavior</i> , 71:615-625 (2003)
	30	Dirk Van Oekelen et al., "5-HT <sub>2A</sub> and 5-HT <sub>2C</sub> receptors and their atypical regulation properties" <i>Life Sciences</i> , Vol. 72:pages 2429-2449 (2003)
	31	Dixit et al., "gents Acting on Central Nervous System: Part XXIII-2-Substituted 1, 2, 3, 4, 6, 7, 12, 12a-Octahydropyrazino[2,1- <i>b</i> ][3] benzazepines & 3-Substituted 1, 2, 3, 4, 4a, 5, 6, 11-Octahydropyrazin[1,2- <i>b</i> ][2] benzazepines", CDRI Communication No. 1969, 893-97 (1974)
	32	Draper, et al., "Novel Stereoselective Syntheses of the Fused Benzazepine Dopamine D <sub>1</sub> Antagonist (6a <i>S</i> , 13 <i>bR</i> )-11-chloro-6, 6a,7,8,9, 13b-hexahydro-7-methyl-5 <i>H</i> -benzo[ <i>d</i> ]naphth[2, 1- <i>b</i> ]azepin-12-ol (Sch 39166): 1. Aziridinium Salt Based Syntheses", <i>Organic Process Research &amp; Development</i> , 2(3):175-85 (1998)
	33	Draper, et al., "Novel Stereoselective Syntheses of the Fused Benzazepine Dopamine D <sub>1</sub> Antagonist (6a <i>S</i> , 13 <i>bR</i> )-11-chloro-6, 6a,7,8,9, 13b-hexahydro-7-methyl-5 <i>H</i> -benzo[ <i>d</i> ]naphth[2, 1- <i>b</i> ]azepin-12-ol (Sch 39166): 2. L-Homophenylalanine-Based Syntheses", <i>Organic Process Research &amp; Development</i> , 2(3):186-93 (1998)
	34	Garrison, "Defining obesity: An adventure in cardiovascular disease epidemiology", <i>Journal of Nutritional Biochemistry</i> (1998), 9(9), 493-500;

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-0048US1	Application No. 10/576,849
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Brian Smith, et al.	
		Filing Date April 9, 2007	Group Art Unit 1624

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	35	Gerritz, et al., "Two General Routes to 1,4-disubstituted-2,3,4,5-tetrahydro-1H-3-benzazepines", <i>Organic Letters</i> , 2(25):4099-102 (2000)
	36	G Di Giovanni et al., "Serotonin/dopamine interaction – Focus on 5-HT <sub>2C</sub> receptor, a new target of psychotropic drugs" <i>Indian Journal of Experimental Biology</i> , Vol. 40:pages 1344-1352 (2002)
	37	Guillory, "Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids", in <i>Polymorphism in Pharmaceutical Solids</i> , ed. Harry G. Brittain, vol. 95, chapter 5, Marcel Dekker, Inc., New York 1999, pages 183-226
	38	Halford, et al., "o-phenylenediacetamide and Other Compounds Related to 3,1H-benzazepine", <i>J. Org. Chem.</i> 17:1646-52 (1952)
	39	Hasan, et. al., "Syntheses of N-chloroacyl-β-phenylethylamine Derivatives", <i>Indian J. Chem.</i> , 9:1022-4 (1971)
	40	Heys, et al., "A New Entry into C7-Oxygenated Tetrahydro-1H-3-benzazepines: Efficient Labeling with Carbon-14 in the Benzo Ring", <i>J. Org. Chem.</i> , 54(19):4702-6 (1989)
	41	Isaac, "The 5-HT <sub>2C</sub> receptor as a potential therapeutic target for the design of antiobesity and antiepileptic drugs" <i>Drugs of the Future</i> (2001), 26(4), 383-393
	42	Kaiser, et al., "6-(phenylthio)-substituted 2,3,4,5-tetrahydro-1H-3-benzazepines, a Novel Class of Dopamine Receptor Antagonists and Neuroleptics", <i>J. Med. Chem.</i> , 23(9):975-6 (1980)
	43	Klein, "Outcome Success in Obesity", <i>Obesity Research</i> , (2001), 9(suppl. 4):354S-358S.
	44	Klohr, et al., "An Intramolecular Photocyclization to Form the Azepino[3,4,5-cd]Indole System", <i>Synthetic Communications</i> 18(7):671-4 (1988)
	45	Küenburg, et al., "Development of a Pilot Scale Process for the Anti-Alzheimer Drug (—)-Galanthamine Using Large-Scale Phenolic Oxidative Coupling and Crystallisation-Induced Chiral Conversion", <i>Organic Process Research &amp; Development</i> , 3(6):425-31 (1999)
	46	Lacivita, Enza et al., "Selective Agents for Serotonin <sub>2C</sub> (5-HT <sub>2C</sub> ) Receptor" <i>Current Topics in Medicinal Chemistry</i> , Vol. 6:pages 1927-1970 (2006)
	47	Lin, et al., "Benzindene Prostaglandins. Synthesis of Optically Pure 15-Deoxy-U-68,215 and its Enantiomer via a Modified Intramolecular Wadsworth-Emmons-Wittig Reaction", <i>J. Org. Chem.</i> , 52(25):5594-601 (1987)
	48	Martin et al. "5-HT <sub>2C</sub> receptor agonists pharmacological characteristics and therapeutic potential", <i>Journal of Pharmacology and Experimental Therapeutics</i> (1998), 286(2), 913-924
	49	Millan, et al., "HT <sub>2C</sub> Receptors Mediate Penile Erections in Rats: Actions of Novel and Selective Agonists and Antagonists", <i>Eur. J. Pharmacol.</i> 325:9-12 (1997)
	50	Nagle, et al., "Efficient Synthesis of β-amino Bromides", <i>Tetrahedron Letters</i> , 41:3011-4 (2000)
	51	Nair, et al., "Preparation of 2,3,4,5-tetrahydro-3,1H-benzazepine-2-one", <i>Indian J. Chem.</i> , 5:169-70 (1967)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-0048US1	Application No. 10/576,849
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Brian Smith, et al.	
		Filing Date April 9, 2007	Group Art Unit 1624

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	52	Neumeyer, et al., "Development of a High Affinity and Stereoselective Photoaffinity Label for the D-1 Dopamine Receptor: Synthesis and Resolution of 7-[ <sup>125</sup> I]Iodo-8-hydroxy-3-methyl-1-(4'-azidophenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine", J. Med. Chem., 33(2):521-6 (1990)
	53	Okuno, et al., "Photocyclization of N-chloroacetyl-2,5-dimethoxyphenethylamine Synthesis of Pyrroloindoles", Chem. Pharm. Bull., 23(11):2584-90 (1975)
	54	Pecherer, et al., "A Novel Synthesis of Aromatic Methoxy and Methylenedioxy Substituted 2,3,4,5-tetrahydro-1H-3-benzazepines", J. Het. Chem., 9:609-16 (1972)
	55	Pfeiffer, et al., "Dopaminergic Activity of Substituted 6-chloro-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines", J. Med. Chem., 25(4):352-8 (1982)
	56	"Remington's Pharmaceutical Sciences" 17 <sup>th</sup> ed., Mack Publishing Company, Easton Pa.: 1418 (1985)
	57	Rosenzweig-Lipson, et al., "Vabicaserin: effects of a novel 5HT <sub>2C</sub> agonist on medial prefrontal cortex neurotransmission, cognition and sensorimotor gating", 20 <sup>th</sup> ECNP Congress, Vienna, Austria (2007)
	58	Tecott, et al., "Eating Disorder and Epilepsy in Mice Lacking 5-HT <sub>2c</sub> Serotonin Receptors", Nature, 374:542-546 (1996)
	59	Vanderlaan, et al., "Synthesis and Oxidative Coupling of (±)-3-oxoreticuline", J. Org. Chem., 50(6):743-7 (1985)
	60	Weinstock, et al., "Separation of Potent Central and Renal Dopamine Agonist Activity in Substituted 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepines", J. Med. Chem., 23(9):973-5 (1980)
	61	Winkler, "Obesity and hemostasis", Archives of Gynecology and Obstetrics (1997), 261(1), 25-29
	62	Wu, et al., "Amino Diol Based Asymmetric Syntheses of a Fused Benzazepine as a Selective D1 Dopamine Receptor", Organic Process Research & Development, 1(5):359-64 (1997)
	63	Yasuda, et al., "A Novel and Stereoselective Synthesis of (±)-cephalotaxine and its Analogue", Tetrahedron Letters, 27(18):2023-6 (1986)
	64	Yonemitsu, et al., "Photocyclization of Pharmacodynamic Amines. IV. Novel Heterocycles from N-chloroacetyl-3,4-dimethoxyphenethylamine", Journal of the American Chemical Society, 92(19):5686-90 (1970)
	65	Yonemitsu, et al., "Photolysis of N-chloroacetyl-O-methyl-L-tyrosine to an Azaazulene", Journal of the American Chemical Society, 89(4):1039-40 (1967)
	66	Yonemitsu, et al., "Photocyclizations of Tyrosines, Tyramines, Catecholamines, and Normescaline", Journal of the American Chemical Society, 90(3):776-84 (1968)
	67	Yonemitsu, et al., "Photocyclization of Pharmacodynamic Amines. II. X-Ray Analysis of a Noncentrosymmetric Tetracyclic Indole", Journal of the American Chemical Society, 90(23):6522-3 (1968)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	